Unresectable Melanoma
Advanced Melanoma Immunotherapy Landscape: Positioning Novel and Emerging Agents
This activity is supported by an educational grant from Merck & Co., Inc.
Melanoma Insights: Focus on High-Risk Early-Stage to Advanced Disease Management
This activity is supported by an educational grant from Merck & Co., Inc.
Immunotherapy combination improves response in unresectable melanoma
An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.
Lifileucel approval the start of a ‘glorious future’ for cell therapy in solid tumors
It took more than 35 years for tumor-infiltrating lymphocytes, which Steven A. Rosenberg, MD, PhD, and colleagues first reported on in 1988 for the treatment of advanced melanoma, to progress enough to gain FDA approval.
Fewer nivolumab doses with ipilimumab appear effective in unresectable melanoma
The first two doses of nivolumab with ipilimumab appeared to drive efficacy and toxicity of the combination among certain patients with melanoma, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program.